PHARMACY **BENEFACT**

Number 1154 · January 2024

A BULLETIN FOR PHARMACY SERVICE PROVIDERS FROM ALBERTA BLUE CROSS®

Temporary benefit added to the *Alberta Drug Benefit List* (ADBL)

Due to the unavailability for Apo-Tamsulosin CR 0.4 mg Extended-Release Tablet (DIN 02362406), Sandoz Tamsulosin CR 0.4 mg Extended-Release Tablet (DIN 02427117) manufactured by Sanis Health Inc., Tamsulosin CR 0.4 mg Extended-Release Tablet (DIN 02429667) manufactured by Sivem Pharmaceuticals ULC, Teva-Tamsulosin CR 0.4 mg Extended-Release Tablet (DIN 02368242) and Flomax CR 0.4 mg Extended-Release Tablet (DIN 02368242) and Flomax CR 0.4 mg Extended-Release Tablet (DIN 02368242) and Flomax CR 0.4 mg Extended-Release Tablet (DIN 02368242) and Flomax CR 0.4 mg Extended-Release Tablet (DIN 02368242) and Flomax CR 0.4 mg Extended-Release Tablet (DIN 02368242) and Flomax CR 0.4 mg Extended-Release Tablet (DIN 02368242) and Flomax CR 0.4 mg Extended-Release Tablet (DIN 02368242) and Flomax CR 0.4 mg Extended-Release Tablet (DIN 02368242) and Flomax CR 0.4 mg Extended-Release Tablet (DIN 02370102) manufactured by Boehringer Ingelheim (Canada) Inc., **Jamp Tamsulosin 0.4 mg Sustained-Release Capsule (DIN 02352419)** will be considered a temporary benefit for the *ADBL*. This grouping was added to the Critical Supply Product List **January 1, 2024**.

As of **January 1, 2024**, all claims for **Jamp Tamsulosin 0.4 mg Sustained-Release Capsule (DIN 02352419)** will be adjudicated to the price published in the most recent *Alberta Blue Cross Drug Price List (ABCDPL)* until further notice. The *ABCDPL* is available online at **ab.bluecross.ca/provider/type/pharmacy/home.php**.

Removal of temporary benefit from the ADBL

Due to the shortages of Apo-Medroxy 10 mg Tablet (DIN 02277298) and Teva-Medroxyprogesterone 10 mg Tablet (DIN 02221306), **Provera 10 mg Tablet (DIN 00729973)** manufactured by Pfizer Canada ULC was added as a temporary benefit for the *ADBL*.

Alberta Blue Cross has confirmed that the shortage for Apo-Medroxy 10 mg Tablet (DIN 02277298) has been resolved.

Provera 10 mg Tablet (DIN 00729973) will no longer be considered a temporary benefit for the ADBL after February 10, 2024.

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at

780-498-8370 (Edmonton and area) 403-294-4041 (Calgary and area) 1-800-361-9632 (toll free) FAX 780-498-8406 (Edmonton and area) FAX 1-877-305-9911 (toll free)



Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims.

Visit ab.bluecross.ca/providers/pharmacy-home.php



**The Blue Cross symbol and name are registered marks of the Canadian Association of Blue Cross Plans, an association of independent Blue Cross plans. Licensed to ABC Benefits Corporation for use in operating the Alberta Blue Cross Plan. *† Blue Shield is a registered trade-mark of the Blue Cross Blue Shield Association. ABC 82320.1154 2024/01